Patent US4622392A successfully refreshed from Google Patents.
US4622392A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Thiophospholipid conjugates of antitumor agents
Assignee: Health Research Inc
•
Filing: 1984-06-21
•
Granted: 1986-11-11
•
Expires: 2004-06-21
Abstract
Abstract This invention relates to cytotoxic compounds. More particularly, this invention relates to conjugates of antitumor agents, and thiophospholipids exhibiting enhanced antitumor activity to methods for producing such compounds and to pharmaceutical compositions containing cytotoxically effective amounts of such compounds as a primary effective ingredient.
Inventors
- 👤 Chung I. Hong
- 👤 Charles R. West
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 14:08
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; C07H19/10; C07H19/16; C07H19/20
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
96 words
A compound selected from the group of compounds having the formula ##STR4## wherein: R 1 is selected from the group consisting of alkyl and alkenyl containing from about 8 to about 22 carbon atoms; A 1 is S; A 3 , A 4 and A 5 are each 0; and X is fatty acyl containing from about 8 to about 22 carbon atoms; sugar is arabinose, esterified to the phosphate moiety at the 5'-position and covalently bonded to the heterocyclic moiety at the 1'-position to form a nucleoside; heterocyclic is cytosime and physiologically acceptable salts thereof.
Claim 2
Dependent Claim
96 words
A compound selected from the group of compounds having the formula ##STR4## wherein: R 1 is selected from the group consisting of alkyl and alkenyl containing from about 8 to about 22 carbon atoms; A 1 is S; A 3 , A 4 and A 5 are each 0; and X is fatty acyl containing from about 8 to about 22 carbon atoms; sugar is arabinose, esterified to the phosphate moiety at the 5'-position and covalently bonded to the heterocyclic moiety at the 1'-position to form a nucleoside; heterocyclic is cytosime and physiologically acceptable salts thereof.
Claim 3
Dependent Claim
1 words
1-β-D-arabinofuranosylcytosine-5'-diphosphate-rac-1-S-hexadecyl-2-0-palmitoyl-1-thioglycerol.
Claim 4
Dependent Claim
1 words
1-β-D-arabinofuranosylcytosine-5'-diphosphate-rac-1-S-hexadecyl-2-0-palmitoyl-1-thioglycerol.
Claim 5
Dependent Claim
1 words
1-β-D-arabinofuranosylcytosine-5'-diphosphaterac-1-S-octadecyl-2-0-palmitoyl-1-thioglycerol.
Claim 6
Dependent Claim
1 words
1-β-D-arabinofuranosylcytosine-5'-diphosphaterac-1-S-octadecyl-2-0-palmitoyl-1-thioglycerol.
Claim 7
Dependent Claim
31 words
A pharmaceutical composition containing from 1 to about 200 mg of a compound as defined by claim 1 in combination with 1 to about 3000 mg of a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-11-10 | 1990-05-12 | 1990-11-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-11-10 | 1994-05-12 | 1994-11-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-11-10 | 1998-05-12 | 1998-11-11 | $7700.00 | Window Closed / Lapsed |